Coil Assisted Flow Diversion Safety and Performance Study

Not Applicable

Completed

• Conditions: Intracranial Aneurysm

• Registration Number: NCT04187573
• Lead Sponsor: Cerus Endovascular, Inc.

Brief Summary

Cerus Endovascular is sponsoring a prospective, single arm, multi-center study to document the safety and performance of Neqstent in adjunctive therapy.

The purpose of the study is to document safety and performance of the Neqstent in adjunctive therapy in treatment for patients with intracranial aneurysms (IA).

Detailed Description

Neqstent is designed as an adjunctive therapy for patients with unruptured and failed bifurcation aneurysm embolizations. Neqstent can be positioned at the neck of the aneurysm with or without existing coils and other embolization products. Embolization coils should be added to fill the dome of the aneurysm after placement of Neqstent.

Study Timeline

• Study First Submitted: 2019-11-27
• Study First Submitted QC: 2019-12-04
• Study First Posted: 2019-12-05
• Study Start: 2020-01-21
• Primary Completion: 2022-06-17
• Study Completion: 2023-11-01
• Status Verified: 2024-10
• Results First Submitted: 2024-10-01
• Results First Submitted QC: 2024-10-01
• Results First Posted: 2024-10-23
• Last Update Submitted: 2024-10-29
• Last Update Posted: 2024-11-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 38

Inclusion Criteria

1. Patient's indication for treatment of unruptured IAs according to the national/international guidelines.
2. Age 18-80 years at screening
3. Patients who are suitable for non-emergency endovascular embolization of saccular IAs
4. IA located at a bifurcation in the anterior or posterior circulation with dimensions consistent with implant size selection guidelines included in the IFU
5. Patient has the necessary mental capacity to participate and is willing and able to participate in the study for the duration of the study follow-up and is able to comply with study requirements
6. Patient able to able to give their informed consent can be included in this study. This must be demonstrated by means of a personally signed and dated informed consent document indicating that the subject has been informed of and understood all pertinent aspects of the study.

Exclusion Criteria

1. Ruptured aneurysm
2. Patient anatomy or physiology considered unsuitable for endovascular treatment
3. Any patient anatomy, physiology, existing implants with failed aneurysm embolization that would interfere with the ability for Neqstent to seal at the neck of the aneurysm. (i.e., compacted coils in close proximity to the neck that prevent good apposition of the Neqstent to the wall of the aneurysm, stent and/or stent-like devices whose struts span the aneurysm neck to retain the coil mass that inhibit access and/or successful Neqstent seating at the aneurysm neck, and/or any aneurysm that has a failed device and confirmed thrombus-burden inside the aneurysm sac)
4. Contraindication for arterial access
5. Largest measured IA neck diameter >8 mm or <3 mm
6. Target IA contains other devices/implants (e.g., coils) that will prevent complete expansion of Neqstent
7. Known allergy to platinum, nickel or titanium
8. Known allergy to contrast agents
9. Contraindication to anticoagulants or platelet inhibitor medication
10. Stenosis of the target IA's parent vessel >50%
11. Anticoagulation medications such as warfarin that cannot be discontinued.
12. Pregnant, breastfeeding or women of childbearing potential not on adequate birth control (only women with a highly effective method of contraception [oral contraception or intra-uterine device] or sterile women can be enrolled to the study)
13. Acute / chronic renal failure (including dialysis); Creatinine > 2.00 mg/dl or > 182 μmol/L
14. Myocardial Infarction, Stroke or TIA within the last 6 months
15. Any other medical issue within the brain that precludes the device implantation such as brain surgery, radiation in the target area of intervention, acute traumatic craniocerebral injury, etc.
16. Other medical conditions that cause an inability to comply with study requirements and/or that could increase the risk of neurovascular procedures or death within 2 years (e.g., liver failure, cancer, heart failure, chronic obstructive pulmonary disease, immunosuppression, neural disease, and hematologic disorders etc.)
17. Participating in another study with investigational devices or drugs that would confound the effects of the study outcomes
18. The presence of condition that may create unacceptable risk during the aneurysm embolization procedure

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
The Proportion of Subjects With Death of Any Non-accidental Cause or Any Major Disabling Stroke After Treatment or Major Disabling Stroke or Death Due to Neurological Cause.	From day 31 to 6 months after treatment
The Proportion of Subjects With Complete Occlusion	6 months	Success will be defined as complete occlusion demonstrated by a Grade 1 using the Raymond Roy Scale.

Trial Locations

Locations (7)

Christian Doppler Klinikum; 🇦🇹 Salzburg, Austria

Alberta Health Sciences; 🇨🇦 Edmonton, Alberta, Canada

Odense University Hospital; 🇩🇰 Odense, Denmark

UK Hamburg; 🇩🇪 Hamburg, Germany

UKSH Kiel; 🇩🇪 Kiel, Germany

Klinikum der Universität München; 🇩🇪 Munich, Germany

Inerespital Basel; 🇨🇭 Basel, Switzerland